Abstract ; Background : The combined inhibition of BRAF and MEK is hypothesized to improve clinical outcomes in patients with melanoma by preventing or delaying the onset of resistance observed with BRAF inhibitors alone. This randomized phase 3 study evaluated the combination of the BRAF inhibitor vemurafenib and the MEK inhibitor cobimetinib. Methods : We randomly assigned 495 patients with previously untreated unresectable locally advanced or metastatic BRAF V600 mutation–positive melanoma ...
Mechanism of action Vemurafenib causes programmed cell death in melanoma cell lines. Vemurafenib interrupts the B-Raf/MEK step on the B-Raf/MEK/ERK pathway − if the B-Raf has the common...
Vemurafenib is a kinase inhibitor used in the treatment of patients with unresectable or metastatic melanoma with the BRAF V600E variant.
On This Page ; General Information About Melanoma · Cellular and Molecular Classification of Melanoma · Stage Information for Melanoma · Treatment Option Overview for Melanoma · Treatment of Stage 0 Melanoma · Treatment of Stage I Melanoma · Treatment of Stage II Melanoma · Treatment of Resectable Stage III Melanoma · Treatment of Unresectable Stage III, Stage IV, and Recurrent Melanoma · Latest Updates to This Summary (04/16/2024) · About This PDQ Summary
Antineoplastic agent; an inhibitor of b-Raf serine-threonine kinase with V600E mutation (BRAF V600E). ; Treatment of unresectable or metastatic melanoma with BRAF V600E mutation (designated an orphan drug by FDA for this use). ; FDA-approved in vitro diagnostic test (e.g., cobas 4800 BRAF V600 Mutation Test) required to confirm presence of BRAF V600E mutation prior to initiation of therapy.
Vemurafenib is a small-molecule inhibitor of the oncogenic BRAF kinase approved for the treatment of melanoma. Here, the scientists involved in the discovery of vemurafenib describe the underlying...
Definition of BRAF · BRAF Mutations in Melanoma · BRAF as a Prognostic Biomarker in Melanoma · BRAF as a Predictive Biomarker in Melanoma · Resistance to BRAF Inhibition · BRAF Testing Recommendations in Melanoma · Ensuring Quality and Timely BRAF Mutation Testing Results
To the Editor: In the study by Chapman et al. (June 30 issue),1 vemurafenib clearly improved rates of overall and progression-free survival among patients with untreated melanoma with the BRAF V600...
Melanoma is the most dangerous type of skin cancer; it develops... (uveal melanoma). In women, melanomas most commonly occur on the legs; while in men, on the back. Melanoma is frequently...
Phase 1 and 2 clinical trials of the BRAF kinase inhibitor vemurafenib (PLX4032) have shown response rates of more than 50% in patients with metastatic melanoma with the BRAF V600E mutation.We cond...